Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + lenvatinib + gemcitabine + cisplatin
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This combination regimen consists of envafolimab, a subcutaneous PD-L1 single-domain antibody, lenvatinib, an oral multi-kinase inhibitor, and the chemotherapy doublet gemcitabine and cisplatin. It is being evaluated as a first-line treatment for patients with advanced biliary tract cancer (BTC). Envafolimab blocks the interaction between PD-L1 and PD-1, enhancing T-cell anti-tumor activity. Lenvatinib inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor proliferation, including VEGFR and FGFR. Gemcitabine and cisplatin provide cytotoxic effects by interfering with DNA synthesis and repair. The regimen is currently being studied in the Phase 2 ENLIGHTEN trial (NCT05410197) led by Sun Yat-sen University.
- Other names
- EnvafolimabLenvatinibGemcitabineCisplatinGemCis
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on envafolimab + lenvatinib + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + lenvatinib + gemcitabine + cisplatin.